Q2 FY2026 EarningsFY26 Q2 results significantly beat consensus across top and bottom lines, with revenue of $2,852M vs. $2,659M expected and GAAP EPS of $0.68 vs. $0.34 expected. Revenue growth of 13% YoY was driven by improved net realized pricing in Salix (+21%) and strong organic performance in Solta Medical (+38%) and Bausch + Lomb (+9%). Operating profit benefited from a 7.00pct reduction in sales deductions, while management successfully navigated major refinancing activities to extend debt maturities to 2030-2032.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Bausch Health(BHC) the Revenue is 2.852 B (+12.73%), Beat estimate;the EBIT is 1.009 B (+41.51%), Beat estimate;the EPS is 0.68 (+70%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
2.85B12.73%
2.66B5.10%
+0.19B7.63%
EBITExceed expectations
1.01B41.51%
0.87B21.46%
+0.14B20.05%
EPSExceed expectations
0.6870.00%
0.392.50%
+0.290072.50%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf